Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Emergence of drug resistance to all available therapies is the major challenge to improving survival in myeloma. Cereblon (CRBN) is the essential binding protein of the widely used immunomodulatory drugs (IMiDs) and novel CRBN E3 ligase modulator drugs (CELMoDs) in myeloma, as well as certain proteo...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Gooding, Sarah, Ansari-Pour, Naser, Towfic, Fadi, Ortiz Estévez, María, Chamberlain, Philip P., Tsai, Kao-Tai, Flynt, Erin, Hirst, Marissa, Rozelle, Dan, Dhiman, Paula, Neri, Paola, Ramasamy, Karthik, Bahlis, Nizar, Vyas, Paresh, Thakurta, Anjan
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2021
Sujets:
Lymphoid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7893409/
https://ncbi.nlm.nih.gov/pubmed/33443552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007081
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires